773 results on '"Ciudin A"'
Search Results
752. A novel case of diabetes MODY1 and chronic hereditary pancreatitis: coexistence of two infrequent genetic mutations.
- Author
-
Cordero-Vázquez E, Filippi-Arriaga F, Hernández IH, Haman SST, and Ciudin A
- Published
- 2021
- Full Text
- View/download PDF
753. Metabolic footprint of aging and obesity in red blood cells.
- Author
-
Domingo-Ortí I, Lamas-Domingo R, Ciudin A, Hernández C, Herance JR, Palomino-Schätzlein M, and Pineda-Lucena A
- Subjects
- Adult, Age Factors, Aged, Female, Healthy Volunteers, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Aging metabolism, Erythrocytes metabolism, Metabolome physiology, Obesity metabolism
- Abstract
Aging is a physiological process whose underlying mechanisms are still largely unknown. The study of the biochemical transformations associated with aging is crucial for understanding this process and could translate into an improvement of the quality of life of the aging population. Red blood cells (RBCs) are the most abundant cells in humans and are involved in essential functions that could undergo different alterations with age. The present study analyzed the metabolic alterations experienced by RBCs during aging, as well as the influence of obesity and gender in this process. To this end, the metabolic profile of 83 samples from healthy and obese patients was obtained by Nuclear Magnetic Resonance spectroscopy. Multivariate statistical analysis revealed differences between Age-1 (≤45) and Age-2 (>45) subgroups, as well as between BMI-1 (<30) and BMI-2 (≥30) subgroups, while no differences were associated with gender. A general decrease in the levels of amino acids was detected with age, in addition to metabolic alterations of glycolysis, the pentose phosphate pathway, nucleotide metabolism, glutathione metabolism and the Luebering-Rapoport shunt. Obesity also had an impact on the metabolomics profile of RBCs; sometimes mimicking the alterations induced by aging, while, in other cases, its influence was the opposite, suggesting these changes could counteract the adaptation of the organism to senescence.
- Published
- 2021
- Full Text
- View/download PDF
754. Robotic Revisional Experience. Single Centre Prospective Cohort Study and Review of the Literature.
- Author
-
Vilallonga R, Cirera de Tudela A, Möller EG, Piñeiro LV, Segura MB, Ferreruela MP, Mata RM, Caubet E, Gonzalez O, Ruiz de Gordejuela AG, Ciudin A, Fort JM, and Carrasco MA
- Subjects
- Female, Humans, Laparoscopy, Male, Reoperation methods, Retrospective Studies, Treatment Outcome, Weight Loss, Bariatric Surgery methods, Obesity, Morbid surgery, Robotic Surgical Procedures
- Abstract
Background: Robotic bariatric surgery (RBS) has increased in recent years. Many doubts continue to exist regarding its utility in terms of postoperative complications, costs and technical aspects. RBS has increased its number and shows a more technical challenge associated with more post-operative complications compared to primary bariatric surgery. We herein present a single institution experience and review to describe its utility in revisional surgery. Methods: A retrospective review of our experience and a review of the literature has been conducted to evaluate the impact of robotic revisional surgery in the bariatric field. Results: A total of 17 patients (5 female and 12 male) were operated on. Most frequent surgery was conversion of sleeve gastrectomy to gastric bypass (n=9). No leaks were found nor severe complications. A systematic review showed similar results including a decreased number for complications when performing robotic revisional surgery. Conclusions: Revisional robotic surgery shows better results compared to standard laparoscopic revisional bariatric surgery in terms of efficacy, safety and hospital stay. No differences were seen in rates of mortality, morbidity and reintervention between both approaches. We encourage surgeons to learn to perform the robotic technique as part of the process of democratization and standardization of bariatric surgery., (Celsius.)
- Published
- 2021
- Full Text
- View/download PDF
755. Sarcopenic obesity: a new challenge in the clinical practice.
- Author
-
Ciudin A, Simó-Servat A, Palmas F, and Barahona MJ
- Abstract
Sarcopenic obesity has been associated with greater disability, morbidity and mortality. However, at present, there are few studies regarding the role of sarcopenia in the evolution of the comorbidities associated with obesity in individuals less than 65 years of age. The pathogenesis is multifactorial and uncompletely ilucidated, but it seems that inflammatory mediators and insulin resistance play an important role. Although there is no clear consensus on its definition and diagnostic methods, there is a growing interest in finding biomarkers useful for the detection and monitoring. Regarding the treatment, a multimodal approach is recomended, based on dietary recommendations, exercise and eventually bariatric surgery., (Copyright © 2020 SEEN y SED. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
756. Effectiveness of Laparoscopic Sleeve Gastrectomy in Super-obese and Non-Super-obese Patients.
- Author
-
Hidalgo M, Vilallonga R, Ruiz de Godejuela AG, Rodríguez-Luna MR, Balibrea JM, Roriz-Silva R, González O, Caubet E, Ciudin A, Armengol M, and Fort JM
- Subjects
- Body Mass Index, Gastrectomy, Humans, Obesity, Postoperative Complications surgery, Prospective Studies, Retrospective Studies, Treatment Outcome, Diabetes Mellitus, Type 2 surgery, Laparoscopy, Obesity, Morbid surgery
- Abstract
Objectives: The primary aim of this study was to assess the effectiveness of sleeve gastrectomy (SG) in super-obese patients. The secondary aim was to identify patient characteristics associated with worse SG outcomes in this group., Methods: A retrospective analysis was carried out of our electronic prospective bariatric surgery patient database, including all patients who underwent SG between January 2007 and January 2017. The sample was divided according to the initial body mass index (BMI) (> or <50 kg/m). The initial characteristics and results in terms of weight loss and comorbidity resolution between the groups were compared. A subanalysis of the variable distributions was carried out according to whether or not the final BMI in the super-obese group had reached <35 kg/m. Data analysis was carried out using STATA 13.1, with a P-value <0.05 considered to be significant., Results: The mean initial BMI was 42.8 kg/m in group 1 (<50 kg/m) and 55 kg/m in group 2 (>50 kg/m). The median follow-up (FU) was 56.2 months. Maximum weight loss was attained at the 18-month FU in both groups (BMI: 28.8 and 34.7 kg/m, respectively). At the 5-year FU, percentage of total weight loss was higher in group 2 and percentage of excess weight loss was statistically higher in group 1 (29.6% vs. 33.1% and 67% vs. 59%, respectively). Outcomes for type 2 diabetes mellitus, hypertension, and dyslipidemia were similar in both groups. The variables associated with attaining a final BMI <35 kg/m in the super-obese group were lower initial BMI, absence of baseline weight-related conditions (type 2 diabetes mellitus, obstructive sleep apnea syndrome, home continuous positive airway pressure, arthropathy, heart disease), and absence of gastroesophageal reflux disease., Conclusions: We observed a statistically significant increase in poor outcomes in patients with a higher initial BMI and with weight-related comorbidities. These parameters could be considered to be potentially good predictors of less satisfactory outcomes in the super-obese patients.
- Published
- 2020
- Full Text
- View/download PDF
757. Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.
- Author
-
Capel M, Ciudin A, Mareque M, Rodríguez-Rincón RM, Simón S, and Oyagüez I
- Abstract
Objective: The aim of this study was to assess the efficiency of exenatide 2 mg/week compared with other glucagon-like peptide-1 (GLP-1) receptor agonists (dulaglutide 1.5 mg/week, liraglutide 1.2 mg/day, liraglutide 1.8 mg/day and lixisenatide 20 μg/day) in adult patients with type 2 diabetes mellitus (T2DM) not adequately controlled on metformin alone from the perspective of the Spanish National Health System (NHS)., Methods: Quality-adjusted life-years (QALYs) gained and total costs of each assessed drug combined with metformin (2 g/day) were estimated over a 40-year time horizon using the Cardiff Diabetes Model (based on UK Prospective Diabetes Study [UKPDS] 68 equations), which simulates disease progression considering the T2DM-related micro- and macrovascular complications, hypoglycaemia, nausea, body mass index (BMI) changes and treatment discontinuation due to adverse effects (AEs). Drug efficacy derived from an indirect comparison performed in a network meta-analysis. Patient characteristics were obtained from the literature. The baseline utility value (0.80) was derived from the PANORAMA study, applying utility decrements to micro- and macrovascular complications, hypoglycaemia episodes and changes in BMI. Treatment discontinuation due to AEs or poorly controlled diabetes (HbA1c > 7.5%) involved switching to second-line (basal insulin) or third-line (basal-bolus insulin) treatment. Total cost (€, 2018) included the costs of drug acquisition, hypoglycaemia, weight gain, micro- and macrovascular complications, nausea and treatment discontinuation due to AEs. An annual discount rate of 3% was applied to costs and outcomes. Deterministic and probabilistic sensitivity analyses (SA) were performed., Results: In base-case, exenatide 2 mg/week resulted in more QALYs (8.26) than dulaglutide 1.5 mg/week (8.19 QALYs), liraglutide 1.2 mg/day (8.10 QALYs), liraglutide 1.8 mg/day (8.20 QALYs) and lixisenatide 20 μg/day (8.13 QALYs). Total cost/patient was €20,423.27 (exenatide 2 mg/week), €22,611.94 (dulaglutide 1.5 mg/week), €21,065.97 (liraglutide 1.2 mg/day), €24,865.69 (liraglutide 1.8 mg/day) and €21,334.58 (lixisenatide 20 μg/day). Deterministic SA confirmed the robustness of the model. In the probabilistic SA, 95-99% of the 1000 Monte Carlo iterations performed were under a hypothetical willingness-to-pay threshold of €20,000/QALY gained., Conclusions: Exenatide 2 mg/week would be a dominant strategy (more effective and less costly) versus the other GLP-1 receptor agonists assessed for the treatment of T2DM patients who are not adequately controlled on metformin alone.
- Published
- 2020
- Full Text
- View/download PDF
758. Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative.
- Author
-
Marquié M, Valero S, Castilla-Marti M, Martínez J, Rodríguez-Gómez O, Sanabria Á, Tartari JP, Monté-Rubio GC, Sotolongo-Grau O, Alegret M, Pérez-Cordón A, Roberto N, de Rojas I, Moreno-Grau S, Montrreal L, Hernández I, Rosende-Roca M, Mauleón A, Vargas L, Abdelnour C, Gil S, Esteban-De Antonio E, Espinosa A, Ortega G, Lomeña F, Pavia J, Vivas A, Tejero MÁ, Gómez-Chiari M, Simó R, Ciudin A, Hernández C, Orellana A, Benaque A, Ruiz A, Tárraga L, and Boada M
- Subjects
- Aged, Brain diagnostic imaging, Brain metabolism, Female, Humans, Male, Middle Aged, Positron-Emission Tomography, Alzheimer Disease diagnosis, Amyloid beta-Peptides metabolism, Cognitive Dysfunction diagnostic imaging, Retina diagnostic imaging, Retina pathology
- Abstract
Background: Optical coherence tomography (OCT) of the retina is a fast and easily accessible tool for the quantification of retinal structural measurements. Multiple studies show that patients with Alzheimer's disease (AD) exhibit thinning in several retinal layers compared to age-matched controls. Subjective cognitive decline (SCD) has been proposed as a risk factor for progression to AD. There is little data about retinal changes in preclinical AD and their correlation with amyloid-β (Aβ) uptake., Aims: We investigated the association of retinal thickness quantified by OCT with Aβ accumulation and conversion to mild cognitive impairment (MCI) over 24 months in individuals with SCD., Methods: One hundred twenty-nine individuals with SCD enrolled in Fundació ACE Healthy Brain Initiative underwent comprehensive neuropsychological testing, OCT scan of the retina and florbetaben (FBB) positron emission tomography (PET) at baseline (v0) and after 24 months (v2). We assessed the association of sixteen retinal thickness measurements at baseline with FBB-PET status (+/-) and global standardize uptake value ratio (SUVR) as a continuous measure at v0 and v2 and their predictive value on clinical status change (conversion to mild cognitive impairment (MCI)) at v2., Results: Mean age of the sample was 64.72 ± 7.27 years; 62.8% were females. Fifteen participants were classified as FBB-PET+ at baseline and 22 at v2. Every 1 μm of increased thickness in the inner nasal macular region conferred 8% and 6% higher probability of presenting a FBB-PET+ status at v0 (OR = 1.08, 95% CI = 1.02-1.14, p = 0.007) and v2 (OR = 1.06, 95% CI = 1.02-1.11, p = 0.004), respectively. Inner nasal macular thickness also positively correlated with global SUVR (at v0: β = 0.23, p = 0.004; at v2: β = 0.26, p = 0.001). No retinal measurements were associated to conversion to MCI over 24 months., Conclusions: Subtle retinal thickness changes in the macular region are already present in SCD and correlate with Aβ uptake.
- Published
- 2020
- Full Text
- View/download PDF
759. Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer's disease in a memory clinic.
- Author
-
Sánchez D, Castilla-Marti M, Marquié M, Valero S, Moreno-Grau S, Rodríguez-Gómez O, Piferrer A, Martínez G, Martínez J, Rojas I, Hernández I, Abdelnour C, Rosende-Roca M, Vargas L, Mauleón A, Gil S, Alegret M, Ortega G, Espinosa A, Pérez-Cordón A, Sanabria Á, Roberto N, Ciudin A, Simó R, Hernández C, Tárraga L, Boada M, and Ruiz A
- Subjects
- Aged, Alzheimer Disease pathology, Biomarkers, Case-Control Studies, Cognitive Dysfunction diagnosis, Cognitive Dysfunction pathology, Female, Humans, Macula Lutea pathology, Male, Alzheimer Disease diagnosis, Macula Lutea diagnostic imaging, Tomography, Optical Coherence
- Abstract
Building on previous studies that report thinning of the macula in Alzheimer's disease (AD) and mild cognitive impairment (MCI) patients, the use of optical coherence tomography (OCT) has been proposed as a potential biomarker for AD. However, other studies contradict these results. A total of 930 participants (414 cognitively healthy people, 192 with probable amnestic MCI, and 324 probable AD patients) from a memory clinic were consecutively included in this study and underwent a spectral domain OCT scan (Maestro, Topcon) to assess total macular volume and thickness. Macular width measurements were also taken in several subregions (central, inner, and outer rings) and in layers such as the retinal nerve fiber (RNFL) and ganglion cell (CGL). The study employed a design of high ecological validity, with adjustment by age, education, sex, and OCT image quality. AD, MCI, and control groups did not significantly vary with regard to volume and retinal thickness in different layers. When these groups were compared, multivariate-adjusted analysis disclosed no significant differences in total (p = 0.564), CGL (p = 0.267), RNFL (p = 0.574), and macular thickness and volume (p = 0.380). The only macular regions showing significant differences were the superior (p = 0.040) and nasal (p = 0.040) sectors of the inner macular ring. However, adjustment for multiple comparisons nullified this significance. These results are not supporting existing claims for the usefulness of macular thickness as a biomarker of cognitive impairment in a memory unit. OCT biomarkers for AD should be subject to further longitudinal testing.
- Published
- 2020
- Full Text
- View/download PDF
760. Author Correction: Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer's disease.
- Author
-
Sánchez D, Castilla-Marti M, Rodríguez-Gómez O, Valero S, Piferrer A, Martínez G, Martínez J, Serra J, Moreno-Grau S, Hernández-Olasagarre B, De Rojas I, Hernández I, Abdelnour C, Rosende-Roca M, Vargas L, Mauleón A, Santos-Santos MA, Alegret M, Ortega G, Espinosa A, Pérez-Cordón A, Sanabria Á, Ciudin A, Simó R, Hernández C, Villoslada P, Ruiz A, Tàrraga L, and Boada M
- Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2019
- Full Text
- View/download PDF
761. The MOPEAD project: Advancing patient engagement for the detection of "hidden" undiagnosed cases of Alzheimer's disease in the community.
- Author
-
Rodríguez-Gómez O, Rodrigo A, Iradier F, Santos-Santos MA, Hundemer H, Ciudin A, Sannemann L, Zwan M, Glaysher B, Wimo A, Bonn J, Johansson G, Rodriguez I, Alegret M, Gove D, Pinó S, Trigueros P, Kivipelto M, Mathews B, Ciudad A, Ferreira D, Bintener C, Gurruchaga M, Westman E, Belger M, Valero S, Maguire P, Krivec D, Kramberger M, Simó R, Garro IP, Visser PJ, Dumas A, Georges J, Jessen F, Winblad B, Shering C, Stewart N, Campo L, and Boada M
- Subjects
- Europe, Humans, Longitudinal Studies, Mass Screening, Neuropsychological Tests, Alzheimer Disease diagnosis, Early Diagnosis, Prodromal Symptoms, Public-Private Sector Partnerships
- Abstract
In most, if not all health systems, dementia is underdiagnosed, and when diagnosis occurs, it is typically at a relatively late stage in the disease process despite mounting evidence showing that a timely diagnosis would result in numerous benefits for patients, families, and society. Moving toward earlier diagnoses in Alzheimer's disease (AD) requires a conscientious and collective effort to implement a global strategy addressing the multiple causes hindering patient engagement at different levels of society. This article describes the design of the Models of Patient Engagement for Alzheimer's Disease project, an ongoing EU-funded public-private multinational initiative that will compare four innovative patient engagement strategies across five European countries regarding their ability to identify individuals with prodromal AD and mild AD dementia, which are "hidden" in their communities and traditionally not found in the typical memory clinic setting. The strategies include an online AD citizen science platform, an open house initiative at the memory clinics, and patient engagement at primary care and diabetologist clinics., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
762. Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer's disease.
- Author
-
Sánchez D, Castilla-Marti M, Rodríguez-Gómez O, Valero S, Piferrer A, Martínez G, Martínez J, Serra J, Moreno-Grau S, Hernández-Olasagarre B, De Rojas I, Hernández I, Abdelnour C, Rosende-Roca M, Vargas L, Mauleón A, Santos-Santos MA, Alegret M, Ortega G, Espinosa A, Pérez-Cordón A, Sanabria Á, Ciudin A, Simó R, Hernández C, Villoslada P, Ruiz A, Tàrraga L, and Boada M
- Subjects
- Aged, Alzheimer Disease metabolism, Biomarkers metabolism, Cohort Studies, Female, Humans, Male, Alzheimer Disease diagnostic imaging, Nerve Fibers metabolism, Tomography, Optical Coherence
- Abstract
The use of optical coherence tomography (OCT) has been suggested as a potential biomarker for Alzheimer's Disease based on previously reported thinning of the retinal nerve fiber layer (RNFL) in Alzheimer's disease's (AD) and Mild Cognitive Impairment (MCI). However, other studies have not shown such results. 930 individuals (414 cognitively healthy individuals, 192 probable amnestic MCI and 324 probable AD) attending a memory clinic were consecutively included and underwent spectral domain OCT (Maestro, Topcon) examinations to assess differences in peripapillary RNFL thickness, using a design of high ecological validity. Adjustment by age, education, sex and OCT image quality was performed. We found a non-significant decrease in mean RNFL thickness as follows: control group: 100,20 ± 14,60 µm, MCI group: 98,54 ± 14,43 µm and AD group: 96,61 ± 15,27 µm. The multivariate adjusted analysis revealed no significant differences in mean overall (p = 0.352), temporal (p = 0,119), nasal (p = 0,151), superior (p = 0,435) or inferior (p = 0,825) quadrants between AD, MCI and control groups. These results do not support the usefulness of peripapillary RNFL analysis as a marker of cognitive impairment or in discriminating between cognitive groups. The analysis of other OCT measurements in other retinal areas and layers as biomarkers for AD should be tested further.
- Published
- 2018
- Full Text
- View/download PDF
763. Assessment of advanced glycation end-products as a biomarker of diabetic outcomes.
- Author
-
Simó-Servat O, Planas A, Ciudin A, Simó R, and Hernández C
- Subjects
- Biomarkers analysis, Forecasting, Glycated Hemoglobin analysis, Humans, Diabetes Complications metabolism, Glycation End Products, Advanced analysis, Glycation End Products, Advanced metabolism
- Abstract
There are substantial differences in the onset and severity of diabetes complications that are not fully explained by HbA1c levels and other risk factors. HbA1c is the gold standard for assessing metabolic control, but has limited value to identify patients at risk of developing diabetic complications. The main disadvantage of HbA1c is that it does not provide information about glycemic variability and does not reflect long-term exposure to hyperglycemia. One of the main pathogenetic mechanisms of diabetic complications is the generation and accumulation of advanced glycation end-products (AGEs). Based on its fluorescence properties, AGEs may be measured in tissues such as the skin or lens. These non-invasive measurements of AGE accumulation may be considered as promising biomarkers of late diabetic complications, and our objective is to summarize the available evidence supporting this statement. However, further translational research and prospective clinical trials are needed before these new biomarkers may be incorporated into clinical practice., (Copyright © 2018 SEEN y SED. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
764. Adrenergic cardiomyopathy and cardiogenic shock as initial presentation of pheochromocytoma. A case report and review of the literature.
- Author
-
Gil-Barrionuevo E, Balibrea JM, Caubet E, Gonzalez O, Vilallonga R, Fort JM, Ciudin A, and Armengol M
- Abstract
Introduction: Pheochromocytomas are infrequent tumors arised from the chromaphine cells of the adrenal sympathetic system. The excess of circulating catecholamines may lead to different cardiovascular disorders from silent alterations of the myocardial conduction to different forms of cardiomyopathy. The onset as cardiogenic shock is exceptional., Presentation of Case: A 35-year-old male, with a known history of acute myopericarditis of unknown origin which debuted as acute pulmonary edema, was admitted with dyspnea in the context of a new heart failure episode with pulmonary edema. An initial ECG showed segmentary repolarization changes, reversed in subsequent ECGs. The echocardiogram showed severe left ventricular dysfunction and lateral and apical hypokinesia. Subsequent echocardiograms showed partial recovery of alterations and preserved systolic function. A cardiac MRI showed a subepicardial minimum catchment focus and myocardial edema suggestive of adrenergic myocarditis. A solid nodular lesion was found in the left adrenal gland, suggesting a pheochromocytoma. Laparoscopic left adrenalectomy confirmed a 30 mm adrenal tumor without signs of locoregional invasion. The patient had normal catecholamine excretion and heart function a few weeks after surgery. Histopathology confirmed the diagnosis of pheochromocytoma., Discussion and Conclusions: Adrenergic cardiomyopathy is a rare entity with a variable clinical presentation. The onset as cardiogenic shock is exceptional. The differential diagnosis of a patient with cardiogenic shock of unknown origin should consider the presence of an underlying pheocromocytoma as well as other states of adrenergic hyperstimulation. The reversibility of the myocardial affection in pheocromocytoma-associated myocardiopathy is common after the tumor resection., (Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
765. Technical Options for Malabsorption Issues After Single Anastomosis Duodenoileal Bypass with Sleeve Gastrectomy.
- Author
-
Vilallonga R, Balibrea JM, Curell A, Gonzalez O, Caubet E, Ciudin A, Ortiz-Zúñiga AM, and Fort JM
- Subjects
- Adult, Biliopancreatic Diversion methods, Duodenum surgery, Female, Gastrectomy methods, Gastric Bypass methods, Humans, Laparoscopy methods, Length of Stay, Male, Middle Aged, Obesity, Morbid metabolism, Postoperative Complications surgery, Quality of Life, Weight Loss, Gastrectomy adverse effects, Gastric Bypass adverse effects, Malabsorption Syndromes etiology, Malabsorption Syndromes surgery, Obesity, Morbid surgery, Reoperation methods
- Abstract
Background: Laparoscopic single anastomosis duodenoileal bypass with sleeve gastrectomy (SADI-S) is a recently developed one- or two-stage operation based on biliopancreatic diversion that is used to treat morbid obesity. Some midterm outcomes suggest that malabsorption is a possible complication following the procedure. Therefore, conversion to a less malabsorptive procedure may be required. We aim to describe and analyze the outcomes after laparoscopic conversion of SADI-S to non-malabsorptive or less malabsorptive procedures., Methods: From January 2015 to April 2017, five patients underwent laparoscopic conversion to single anastomosis duodenojejunal bypass with sleeve gastrectomy (SADJ-S) (video) following SADI-S, and one female patient underwent laparoscopic conversion to gastric bypass (GBP) following SADI-S, after presenting with severe protein-calorie malnutrition, nutritional deficiencies, poor quality of life, or increased number of bowel movements., Results: Mean preoperative BMI was 24.0 kg/m
2 (20.4-27.5 kg/m2 ). Four patients underwent SADI-S to SADJ-S conversions and one underwent a SADI-S to Roux-en-Y duodenojejunal bypass. All cases were performed laparoscopically. No relevant postoperative complications or mortality was reported and the mean hospital stay was 4.6 days. Malabsorptive symptoms resolved in all patients. All patients experienced weight regain. Mean BMI increase was 7.1 kg/m2 (5-10.8 kg/m2 )., Conclusions: Outcomes of laparoscopic conversion to SADJ-S or GBP after SADI-S were acceptable, showing clinical improvement of malnutrition, nutritional deficiencies, and quality of life in all cases. Weight regain must be advised. These techniques appear feasible and free of severe long-term complications. Further investigation is warranted to understand the best common channel length for patients undergoing SADI-S.- Published
- 2017
- Full Text
- View/download PDF
766. Retinal Microperimetry: A New Tool for Identifying Patients With Type 2 Diabetes at Risk for Developing Alzheimer Disease.
- Author
-
Ciudin A, Simó-Servat O, Hernández C, Arcos G, Diego S, Sanabria Á, Sotolongo Ó, Hernández I, Boada M, and Simó R
- Subjects
- Aged, Aged, 80 and over, Case-Control Studies, Female, Fluorodeoxyglucose F18, Humans, Magnetic Resonance Imaging, Male, Positron-Emission Tomography, Prospective Studies, Alzheimer Disease etiology, Diabetes Mellitus, Type 2 complications, Visual Field Tests
- Abstract
Type 2 diabetes is associated with a high risk of cognitive impairment and dementia. Therefore, strategies are needed to identify patients who are at risk for dementia. Given that the retina is a brain-derived tissue, it may provide a noninvasive way to examine brain pathology. The aims of this study were to evaluate whether retinal sensitivity 1 ) correlates with the specific parameters of brain imaging related to cognitive impairment and 2 ) discriminates patients with diabetes with mild cognitive impairment (MCI) from those with normal cognition and those with Alzheimer disease (AD). For this purpose, a prospective, nested case-control study was performed and included 35 patients with type 2 diabetes without cognitive impairment, 35 with MCI, and 35 with AD. Retinal sensitivity was assessed by Macular Integrity Assessment microperimetry, and a neuropsychological evaluation was performed. Brain neurodegeneration was assessed by MRI and fludeoxyglucose-18 positron emission tomography (
18 FDG-PET). A significant correlation was found between retinal sensitivity and the MRI and18 FDG-PET parameters related to brain neurodegeneration. Retinal sensitivity was related to cognitive status (normocognitive > MCI > AD; P < 0.0001). Our results suggest that retinal sensitivity assessed by microperimetry is related to brain neurodegeneration and could be a useful biomarker for identifying patients with type 2 diabetes who are at risk for developing AD., (© 2017 by the American Diabetes Association.)- Published
- 2017
- Full Text
- View/download PDF
767. PREventive Care Infrastructure based On Ubiquitous Sensing (PRECIOUS): A Study Protocol.
- Author
-
Castellano-Tejedor C, Moreno J, Ciudin A, Parramón G, and Lusilla-Palacios P
- Abstract
Background: mHealth has experienced a huge growth during the last decade. It has been presented as a new and promising pathway to increase self-management of health and chronic conditions in several populations. One of the most prolific areas of mHealth has been healthy lifestyles promotion. However, few mobile apps have succeeded in engaging people and ensuring sustained use., Objective: This paper describes the pilot test protocol of the PReventive Care Infrastructure based on Ubiquitous Sensing (PRECIOUS) project, aimed at validating the PRECIOUS system with end users. This system includes, within a motivational framework, the Bodyguard2 sensor (accelerometer with heart rate monitoring) and the PRECIOUS app., Methods: This is a pilot experimental study targeting morbidly obese prediabetic patients who will be randomized to three conditions: (1) Group 1 - Control group (Treatment as usual with the endocrinologist and the nurse + Bodyguard2), (2) Group 2 - PRECIOUS system (Bodyguard2 + PRECIOUS app), and (3) Group 3 - PRECIOUS system (Bodyguard2 + PRECIOUS app + Motivational Interviewing). The duration of the study will be 3 months with scheduled follow-up appointments within the scope of the project at Weeks 3, 5, 8, and 12. During the study, several measures related to healthy lifestyles, weight management, and health-related quality of life will be collected to explore the effectiveness of PRECIOUS to foster behavior change, as well as user acceptance, usability, and satisfaction with the solution., Results: Because of the encouraging results shown in similar scientific work analyzing health apps acceptance in clinical settings, we expect patients to widely accept and express satisfaction with PRECIOUS. We also expect to find acceptable usability of the preventive health solution. The recruitment of the pilot study has concluded with the inclusion of 31 morbidly obese prediabetic patients. Results are expected to be available in mid-2017., Conclusions: Adopting and maintaining healthy habits may be challenging in people with chronic conditions who usually need regular support to ensure mid/long-term adherence to recommendations and behavior change. Thus, mHealth could become a powerful and efficient tool since it allows continuous communication with users and immediate feedback. The PRECIOUS system is an innovative preventive health care solution aimed at enhancing inner motivation from users to change their lifestyles and adopt healthier habits. PRECIOUS includes ubiquitous sensors and a scientifically grounded app to address three main components of health: physical activity, diet, and stress levels., Trial Registration: Clinicaltrials.gov NCT02818790; https://clinicaltrials.gov/ct2/show/NCT02818790 (Archived by WebCite at http://www.webcitation.org/6qfzdfMoU)., (©Carmina Castellano-Tejedor, Jordi Moreno, Andrea Ciudin, Gemma Parramón, Pilar Lusilla-Palacios. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 31.05.2017.)
- Published
- 2017
- Full Text
- View/download PDF
768. Cognitive impairment and dementia: a new emerging complication of type 2 diabetes-The diabetologist's perspective.
- Author
-
Simó R, Ciudin A, Simó-Servat O, and Hernández C
- Subjects
- Aging metabolism, Alzheimer Disease diagnosis, Alzheimer Disease epidemiology, Alzheimer Disease metabolism, Animals, Cognitive Dysfunction diagnosis, Cognitive Dysfunction epidemiology, Dementia diagnosis, Dementia epidemiology, Diabetes Complications diagnosis, Diabetes Complications epidemiology, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 epidemiology, Glycation End Products, Advanced metabolism, Humans, Insulin metabolism, Oxidative Stress physiology, Cognitive Dysfunction metabolism, Dementia metabolism, Diabetes Complications metabolism, Diabetes Mellitus, Type 2 metabolism
- Abstract
Type 2 diabetes mellitus (T2D) and Alzheimer's disease (AD) are two of the most common diseases of aging around the world. Given the frequency with which T2D and AD occur, the notion that people with T2D may be at increased risk for AD has large societal consequences, and understanding the mechanistic links between these diseases is imperative for the development of effective AD prevention and treatment strategies. Apart from being an accelerator of AD, T2D is associated with a progressive cognitive decline. Impaired insulin signaling, inflammation, the accumulation of advanced glycation end-products and oxidative stress all play an essential role in the pathogenesis of both AD and diabetic complications. Therefore, it is reasonable to postulate that these pathways are involved in the increased risk of dementia that occurs in the T2D population. The early diagnosis of cognitive impairment and the identification of the subset of patients at a higher risk of developing AD is a challenge for healthcare providers, and meeting it will permit us to implement a personalized medicine, which is an essential issue in diabetes care with significant therapeutic implications. The main gaps that should be filled to achieve this objective are examined.
- Published
- 2017
- Full Text
- View/download PDF
769. Diabetes mellitus and Alzheimer's disease: An unforgettable relation.
- Author
-
Ciudin A
- Subjects
- Alzheimer Disease genetics, Alzheimer Disease pathology, Atrophy, Cognition Disorders etiology, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 pathology, Diabetes Mellitus, Type 2 physiopathology, Diabetic Neuropathies pathology, Diabetic Neuropathies physiopathology, Diabetic Retinopathy physiopathology, Diffusion Tensor Imaging, Disease Progression, Genetic Predisposition to Disease, Humans, Insulin Resistance, White Matter pathology, Alzheimer Disease etiology, Diabetes Mellitus, Type 2 psychology, Diabetic Neuropathies psychology, Nerve Degeneration etiology
- Published
- 2016
- Full Text
- View/download PDF
770. [Non- PSA serum markers for the diagnosis of PCa].
- Author
-
Mengual L, Musquera M, Ciudin A, and Ribal MJ
- Subjects
- Biomarkers, Tumor blood, Blood Proteins analysis, Humans, Male, Nucleic Acids blood, Prostate-Specific Antigen, Prostatic Neoplasms blood, Prostatic Neoplasms diagnosis
- Abstract
Prostate cancer (PCa) is the most common male malignancy in our population. Over the past two decades, the prostate specific antigen (PSA) has been widely used for screening, diagnosis and monitoring of prostate cancer. Routine use of PSA has been continuing subject to controversy due to its limited specificity, which is derived from the fact that serum PSA levels are produced in a variety of non-neoplastic conditions. The shortcomings in sensitivity and specificity of PSA have promoted the search for new biomarkers to improve diagnostic performance. The ultimate goal is to get those diagnosing clinically significant prostate tumors and to individualize treatment in this disease. Among the biomarkers studied in prostate cancer we could found tissue biomarkers as well as serum or urine biomarkers. In this paper we proceed to review those serum biomarkers not related to PSA that have been published in the literature.
- Published
- 2015
771. Measurement of waist circumference for retrospective studies - prospective validation of use of CT images to assess abdominal circumference.
- Author
-
Ciudin A, Salvador R, Budoy A, Ciudin A, Spinu C, Diaconu MG, Constantin V, Sánchez J, Nicolau C, and Alcaraz A
- Subjects
- Adult, Aged, Body Weights and Measures methods, Female, Humans, Male, Middle Aged, Prospective Studies, Retrospective Studies, Tomography, X-Ray Computed, Waist Circumference
- Abstract
Introduction: To validate the use of supine position and CT images for assessing abdominal circumference (AC)., Method: A prospective study in consecutive patients undergoing scheduled abdominal CT at our center between 17 and 25 September 2012. AC was measured four times: Measurements 1 and 2 were sequentially done by the same trained nurse before abdominal CT just above the iliac crest, while measurements 3 and 4 were done on the last abdominal CT slice not showing the iliac bone. Student's t tests and Q-Q and Bland-Altman plots were used for statistical analysis., Results: A total of 102 patients were recruited. Mean age, 60 (35-78) years. Mean BMI, 25 (18-39) kg/m(2). Mean AC, 93.2 (73-135) cm. No significant differences were found between the four ACs measured (Student's t test, P=0.83). Q-Q and Bland-Altman plots showed good overlapping for the low and central values (73-110 cm) with a greater scatter for extremely high values. For the ellipse estimation, R(2) was 0.987 with a mean error of 0.4 cm and a stretch dispersion between 1.1 and -0.3 cm., Conclusion: Supine (either measured or estimated on CT images by free hand elliptical ROI or ellipse formula) and standing measurements appear to be equivalent for abdominal circumferences <110 cm., (Copyright © 2013 SEEN. Published by Elsevier Espana. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
772. [Interns' viewpoints and knowledge about management of hyperglycemia in the hospital setting].
- Author
-
Biagetti B, Ciudin A, Portela M, Dalama B, and Mesa J
- Subjects
- Clinical Competence, Humans, Surveys and Questionnaires, Hospitalization, Hyperglycemia drug therapy, Internship and Residency
- Abstract
Background and Objective: In many hospitals, adequate glycemic control is not achieved despite implementation of new insulin therapy protocols. Our aim was to assess resident physician' attitudes toward inpatient hyperglycemia, barriers to achieve optimum control, and impact on them of an insulin training program, Material and Methods: A questionnaire was used to assess understanding and standard management of hyperglycemia before and six months after implementation of an inpatient insulin treatment program., Results: Twenty-five interns completed the questionnaire. Glycemic control was considered "very important" in all admission situations, but was only considered "very important" in conventional hospitalization by 36% of interns. Most of these felt "comfortable" using sliding scales, but not with the basal/bolus regimen, which was the least commonly used. Perception of number of well-controlled patients and comfort and use of basal/bolus therapy increased at six months, but use of "sliding scales" remained high. The greatest difficulty reported for adequate management of hyperglycemia was the lack of knowledge., Conclusions: Most residents are aware of the importance of adequate glycemic control, but cannot achieve it because of inadequate knowledge. The insulin training program led to an improved perception and applicability of basal-bolus insulin regimens. However, despite all efforts, use of sliding scales remains high. Training programs should emphasize management of hyperglycemia., (Copyright © 2012 SEEN. Published by Elsevier Espana. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
773. [Viral small bowel intussusception: a rare cause of intestinal obstruction].
- Author
-
Constantin V, Ciudin A, and Popa F
- Subjects
- Aged, Female, Humans, Ileal Diseases diagnosis, Ileal Diseases surgery, Intussusception diagnosis, Intussusception surgery, Middle Aged, Treatment Outcome, Ileal Diseases virology, Ileocecal Valve, Intestinal Obstruction virology, Intussusception virology
- Abstract
Representing a rare cause of bowel obstruction, the ileal intussusception is commonly met in the pediatric surgery. Even if in children's cases the symptoms can mimick a multitude of abdominal syndromes, usually in adult cases the symptoms fit the pattern of the intestinal obstruction. This paper presents 2 clinical cases of small bowel intussusception in adult, the particularity of cases being that the pathogenesis couldn't be established first hand; the pathology exam revealed only minor inflammatory responses,including modest reactive lymph nodes in the vicinity of lesions, without further alterations. The etiology of bowel intussusception was finally attributed to viral infection with gastroenteritis, based on clinical and pathological criteria.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.